SynthesisAdvances in experimental medicine and biology2021
A Paradigm Gap in Host-Pathogen Interaction Studies: Lesson from the COVID-19 Pandemic.
Synthesis in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCOVID-19 outbreak displayed presumably an increased accumulation of SARS-CoV-2 virus during comorbid complications and a substantial variation in the mortality within and between the countries, which in turn siren us the lack of knowledge in host-pathogen interactions (HPIs). Our aim is to describe the lessons taught by the COVID-19 pandemic in the existing/missing investigations on HPI.
methodsThis was from a retrospective meta-analysis of literature on "COVID-19 and comorbidity" to expose the existing paradigm gap in HPI by highlighting the omitted concepts/areas of research and new approaches to consider for the development of future therapeutics.
resultsLiterature on "COVID-19 and comorbidity" apparently depicted the disparity in HPI during comorbid/immune-challenged conditions, which was reflected in the poor prognosis of the disease and failed therapeutics upon clinical trials. Moreover, the entry, adherence, multiplication, and the following establishment of infection were also varied in groups with various comorbidities. This edified that the mode of interaction of an infectious agent could vary according to the immunological and health status of the host system and hence the efficiency/success rate of treatment modalities. In addition, limited number of literature on HPI upon comorbid and immune-challenged conditions of the host manifestly indicated that there is a lack of our focus/attention on consideration of the host immune/health-specific factors in HPI studies. These alert us that the development of unambiguous therapeutic approaches is needed for a better/successful treatment of novel infectious agents in the future.
conclusionBy understanding the immunological state exhibited in SARS-CoV-2 infection, we conclude that the COVID-19 pandemic has taught us a great lesson that our current understanding of HPI is insufficient to fight and conquer novel infections in real life. Hence, newer approaches are obligatory to understand HPI in order to combat COVID-19-like outbreaks in the future, if any, and also to design novel immunogenic/nutraceutical-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.